COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
We compared vaccine effectiveness (VE) against severe COVID-19 during calendar periods from December 2021 to March 2022 when Omicron BA.1 and BA.2, respectively, were the dominating virus variants in Scania county, Sweden. We used continuous density case-control sampling matched for sex and age, and with further adjustment for differences in comorbidities and prior infection. VE remained relatively stable after the transition from BA.1 to BA.2 among people with at least three doses but decreased markedly among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. These findings suggest that booster vaccination is needed to maintain sufficient protection against severe COVID-19.
Article activity feed
-
SciScore for 10.1101/2022.04.14.22273896: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A major limitation was that we lacked data on virus variant for the individual cases in each time period. Our study may therefore underestimate the true change in VE associated with the transition from BA.1 to BA.2. Another limitation was that we could not …
SciScore for 10.1101/2022.04.14.22273896: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A major limitation was that we lacked data on virus variant for the individual cases in each time period. Our study may therefore underestimate the true change in VE associated with the transition from BA.1 to BA.2. Another limitation was that we could not evaluate protection from prior Omicron infection, as the follow up period with Omicron dominance is still short. Evidence from Qatar suggests that infection from BA.1 protects against reinfection with BA.2 but this was observed during a very short follow up period (10). A further limitation of our study was that general testing was no longer generally recommended, which means that VE against infection could not be evaluated. It should also be noted that the statistical uncertainty in some of our subgroups were substantial, as reflected in the wide confidence intervals. Continued monitoring of VE associated with Omicron BA.2 is therefore warranted.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
